摘要
目的 探讨在疑难淋巴组织增生疾病中BIOMED-2基因重排检测的诊断价值.方法 对874例疑难淋巴组织增生性疾病进行BIOMED-2克隆性分析和免疫组化染色,并对相关病例进行了EBER原位杂交、HP核酸测定.结果 疑难淋巴组织增生性病变874例,经检测确诊为恶性淋巴瘤565例,其中经典型霍奇金氏恶性淋巴瘤55例,B型细胞非霍奇金恶性淋巴瘤359例,BIOMED克隆性分析阳性率为10.5％～85.7％,T细胞非霍奇金氏恶性淋巴瘤112例,BIOMED克隆性分析阳性率在0％ ～ 88％.结论 BIOMED-2克隆性分析对疑难的T细胞淋巴瘤诊断帮助较大.对于免疫组化bcl-2染色阴性的滤泡性淋巴瘤检测阳性率较高.如果标本前期处理不规范或者恶性细胞比率过低就会造成假阴性结果.
Objective To investigate the diagnostic value of BIOMED-2 gene rearrangement detection in difficult lymphoid proliferative disease. Methods From April 2010-December 2013 874 cases of patients with incurable lymphatic tissue proliferative disease , carried BIOMED-2 clone detection and analysis of immunohistochemical staining , and related cases were EBER in situ hybridization, HP nucleic acid determination. Results In 874 cases of difficult lymphoproliferative disease, the detection of 565 cases were diagnosed as malignant lymphoma , including classic Hodgkin lymphoma 55 cases , B -cell non- Hodgkin＇s lymphoma 398 cases, BIOMED positive clonal analysis rate between 10.53% 85.71% , and T - cell non- Hodgkin＇s lymphoma 112 cases , BIOMED elonal analysis of positive rate between 0% to 88.00% . Conclusions The contribution of BIOMED-2 clonal analysis to the diagnosis of T-cell lymphoma was more significant. Follicular lymphoma was higher positive rate with bcl-2 immunohistochemical staining negative. If the pre-treatment in samples is not standardized or malignant cells ratio is too low would cause false negative results.
出处
《诊断病理学杂志》
CSCD
北大核心
2014年第6期388-390,共3页
Chinese Journal of Diagnostic Pathology
基金
辽宁省自然科学基金项目(编号:20102246)
国家自然科学基金项目(编号:51374068)
